Abstracts tagged "autoimmune diseases"

Abstract Number: 1449 • ACR Convergence 2020
Altered Splicing in Leukocytes from Patients with Antiphospholipid Syndrome, Systemic Lupus Erythematosus and Antiphospholipid Syndrome with Lupus: Clinical Involvement
Alejandra Maria Patiño-Trives¹, Alejandro Ibáñez-Costa², Carlos Pérez-Sánchez¹, Laura Pérez-Sanchez³, Maria Luque-Tevar¹, Iván Arias de la Rosa¹, María-Carmen Abalos-Aguilera¹, Desirée Ruiz-Vilchez⁴, Pedro Segui⁵, Mario Espinosa⁵, Nuria Barbarroja¹, Eduardo Collantes⁴, Justo P. Castaño⁵, Raul M Luque⁵, María de los ángeles Aguirre-Zamorano⁵ and Chary Lopez-Pedrera¹, ¹Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, ³Hospital Universitario Reina Sofía, Córdoba, Spain, ⁴Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba
Background/Purpose: To identify shared and differential changes in the splicing machinery of immune cells from antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome…
Abstract Number: 1580 • ACR Convergence 2020
Generalized Immune Activation in Structures Related to PMR or GCA on PET/CT Assessment Does Not Occur in Immune Checkpoint Inhibitor-Treated Patients Who Do Not Go on to Develop Rheumatic Immune-Related Adverse Events
David Liew¹, Aurora Poon², Christopher McMaster³, Claire Owen⁴, Jessica Leung⁵, Albert Frauman², Jonathan Cebon⁶, Andrew Scott⁶ and Russell Buchanan⁷, ¹Austin Health, Melbourne, Victoria, Australia, Heidelberg, Victoria, Australia, ²Austin Health, Melbourne, Victoria, Australia, Melbourne, Victoria, Australia, ³Austin Health, Melbourne, Victoria, Australia, Pascoe Vale South, Victoria, Australia, ⁴Austin Health, Melbourne, Victoria, Australia, Ashburton, Victoria, Australia, ⁵Austin Health, Melbourne, Victoria, Australia, Melbourne, ⁶Austin Health, Melbourne, Victoria, Australia, Melbourne, Australia, ⁷Austin Health, Melbourne, Victoria, Australia, Heidelberg, Melbourne, Victoria, Australia
Background/Purpose: The pathogenesis of rheumatic immune-related adverse events (irAEs) from checkpoint inhibitor cancer immunotherapy directed against programmed cell death protein 1 (PD-1) and programmed death…
Abstract Number: 2038 • ACR Convergence 2020
Characterizing Morphea Subsets Using a Multi-center, Prospective, Cross-sectional Analysis
Jane Zhu¹, Smriti Prasad², Kaila Schollaert-Fitch³, Robert Haley⁴, Kathryn Torok³ and Heidi Jacobe², ¹UT Southwestern Medical Center, Dallas, ²University of Texas Southwestern Medical Center, Dallas, TX, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Texas Southwestern Medical Center, Dallas
Background/Purpose: Morphea, or localized scleroderma, is an inflammatory condition of the skin and soft tissue that results in excessive collagen deposition, often producing permanent functional…
Abstract Number: 0011 • ACR Convergence 2020
Patients Receiving Cytokine Inhibitors Have Low Prevalence of SARS-CoV-2 Infection
David Simon¹, Koray Tascilar¹, Gerhard Krönke², Arnd Kleyer¹, Mario Zaiss³, Franz Heppt⁴, Christine Meder⁴, Raja Atreya⁵, Entcho Klenske⁵, Peter Dietrich⁵, Abdullah Abdullah⁵, Thorsten Kliem⁵, Giulia Corte⁶, Harriet Morf³, Moritz Leppkes⁵, Andreas Kremer⁵, Andreas Ramming³, Milena Pachowsky⁷, Florian Schuch⁸, Monika Ronneberger⁹, Stefan Kleinert¹⁰, Clara Maier¹¹, Axel Hueber¹², Karin Manger¹³, Bernhard Manger³, Carola Berking⁴, Matthias Tenbusch¹¹, Klaus Überla¹¹, Michael Sticherling³, Markus Neurath⁵ and Georg Schett¹⁴, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Georgia, ³Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Department of Dermatology, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Department of Internal Medicine 1, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁶Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Gibraltar, ⁷Department of Orthopedic and Trauma Surgery, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁸Rheumatology Clinical Practice Erlangen, Erlangen, Ghana, ⁹Rheumatology Clinical Practice Erlangen, Erlangen, Germany, ¹⁰Rheumatology-Nephrology Practice, Erlangen, Germany, ¹¹Institute of Clinical and Molecular Virology, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ¹²Sozialstiftung Bamberg, Sektion Rheumatologie, Bamberg, Germany, ¹³Rheumatology Practice Bamberg, Bamberg, Germany, ¹⁴Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: Therapeutic interventions for Immune-mediated inflammatory diseases (IMIDs) target cytokines, such as TNF-a, IL-6, IL-17 and IL-23, which are involved in the physiological and pathological…
Abstract Number: 0299 • ACR Convergence 2020
The Minor Protective Allele at rs1876453 Is Associated with Increased Age of Onset of Systemic Lupus Erythematosus
Ani Oganesyan¹, Jennifer Kelly², Stuart Glenn², Adam Adler², Adrienne Williams³, Mary Comeau⁴, Julia Ziegler⁵, Miranda Marion⁵, Marta Alarcón-Riquelme⁶, Graciela Alarcón⁷, Juan-Manuel Anaya⁸, Sang-Cheol Bae⁹, Dam Kim⁹, Lee Hye-Soon⁹, Lindsey Criswell¹⁰, Barry Freedman¹¹, Gary Gilkeson¹², Joel Guthridge¹³, Chaim Jacob¹⁴, Judith James¹⁵, Diane Kamen¹⁶, Joan Merrill¹⁷, Kathy Moser Silvis¹⁸, Timothy Niewold¹⁹, Michelle Petri²⁰, Rosalind Ramsey-Goldman²¹, John Reveille²², Hal Scofield²³, Anne Stevens²⁴, Luis Vilá²⁵, Timothy Vyse²⁶, Kenneth Kaufman²⁷, John Harley²⁸, Carl Langefeld⁵, Patrick Gaffney², Elizabeth Brown²⁹, Jeffrey Edberg⁷, Robert Kimberly⁷, Betty Tsao¹², Daniela Ulgiati³⁰, Kenneth Jones³¹ and Susan Boackle³², ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Department of Biostatistical Sciences and Center for Public Health Genomics Wake Forest School of Medicine, Winston-Salem,, NC, ⁴Department of Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine; MC Analytics, Winston-Salem, NC, ⁵Department of Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, NC, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica, Granada (GENYO), Granada, Spain, ⁷Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁸Center for Autoimmune Diseases Research (CREA), Universidad del Rosario, Bogotá, Colombia, ⁹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹⁰Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA, ¹¹Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem,, NC, ¹²Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ¹³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oaklahoma, OK, ¹⁴Department of Medicine, University of Southern California, Los Angeles, CA, ¹⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK, ¹⁶Medical University of South Carolina, Charleston, SC, ¹⁷Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁹Colton Center for Autoimmunity, NYU School of Medicine, New York, NY, ²⁰Johns Hopkins University School of Medicine, Baltimore, ²¹Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²²Department of Internal Medicine, University of Texas, Houston, TX, ²³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Charleston, SD, ²⁴Janssen Pharmaceuticals, Spring House, PA, ²⁵Division of Rheumatology, Department of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ²⁶Division of Genetics and Molecular Medicine and Immunology, King’s College, London, United Kingdom, ²⁷Cincinnati Children’s Hospital Medical Center;US Department of Veterans Affairs Medical Center, Cincinnati, OH, ²⁸Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, OH, ²⁹Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, ³⁰School of Pathology and Laboratory Medicine, Centre for Genetic Origins of Health and Disease, The University of Western Australia, Crawley, Australia, ³¹Harold Hamm Diabetes Center, University of Oklahoma Health Science Center, Oklahoma City, OK, ³²Division of Rheumatology, University of Colorado School of Medicine; Denver Veterans Affairs Medical Center, Aurora, CO
Background/Purpose: Systemic lupus erythematosus (SLE) is a clinically heterogenous autoimmune disease characterized by autoantibody- and complement-mediated inflammatory damage to multiple organ systems. We previously showed…
Abstract Number: 0558 • ACR Convergence 2020
Statin Use Pattern in Patients with Inflammatory Joint Disease in a Single Site VA Medical Center
Lenche Kostadinova¹, Sofi Damjanovska², Angela Gupta³, Ibtissam Gad⁴, Sameena Syed⁴, Alyssa Lange⁵, Corinne Kowal⁶, Carey Shive⁷, Christopher Burant⁴, Brigid Wilson⁴, David Canaday⁴, David Zidar⁸, Donald Anthony⁹ and Maya Mattar¹⁰, ¹(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Highland Heights, OH, ²(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH, ³(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, ⁴(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, ohio, ⁵Case Western Reserve University, Cleveland, ⁶Case western reserve university/Cleveland VA Medical Center, ohio, ⁷(2) Department of Pathology, Case Western Reserve University, ohio, ⁸Case Western Reserve University/Cleveland VA Medical Center, Cleveland, ⁹Case Western Reserve University/Cleveland VA Medical Center/MetroHealth Medical Center, Cleveland, OH, ¹⁰Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH
Background/Purpose: Patients with inflammatory joint disease, including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) carry increased risk of cardiovascular disease (CVD). Mechanisms…
Abstract Number: 0843 • ACR Convergence 2020
Rab4A Activation Predisposes to Hepatitis in Spontaneous and Pristane-Induced Mouse Models of Systemic Lupus Erythematosus
Nick Huang¹, Akshay Patel¹, Zachary Oaks¹ and Andras Perl¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: HRES-1/Rab4 or Rab4A, a GTPase responsible for mitochondrial oxidative stress1 and activation of the mechanistic target of rapamycin2, is overexpressed in T cells of…
Abstract Number: 1048 • ACR Convergence 2020
Reduced Decline in Forced Vital Capacity in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs) Treated with Nintedanib
Eric Matteson¹, Oliver Distler², Jörg HW Distler³, Masataka Kuwana⁴, Janet Pope⁵, James Seibold⁶, Alexandra James⁷, Rozsa Schlenker-Herceg⁸, Klaus Rohr⁷ and Kevin Flaherty⁹, ¹Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, MN, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ³University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Tokyo, Japan, ⁵Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁶Scleroderma Research Consultants LLC, Aiken, South Carolina, USA, Aiken, SC, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, ⁹Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI
Background/Purpose: In the randomized placebo-controlled INBUILD trial in patients with chronic fibrosing ILDs with a progressive phenotype, nintedanib reduced the rate of decline in forced…
Abstract Number: 1287 • ACR Convergence 2020
Prevalence of Morbidity Prior to Diagnosis of Incident Systemic Lupus Erythematosus in the Danish Population
Julia Simard¹, Mikkel Faurschou², Soeren Jacobsen² and Renata Hansen², ¹Stanford Medicine, Stanford, CA, ²Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark
Background/Purpose: Patients with SLE experience a high burden of various comorbidities at disease onset and during disease progression. Studies of excess morbidity prior to SLE…
Abstract Number: 1450 • ACR Convergence 2020
Integrative Analysis of DNA Methylation and Gene Expression in Monocytes from Primary Antiphospholipid Syndrome Patients Identifies a Gene Expression Signature Associated with Their Atherothrombotic Phenotype
Carlos Pérez-Sánchez¹, M Angeles Aguirre², Alejandra Maria Patiño-Trives¹, Laura Pérez-Sanchez³, Maria Luque-Tevar¹, Iván Arias de la Rosa¹, María-Carmen Abalos-Aguilera¹, Pedro Segui⁴, Javier Rodriguez-Ubreva⁵, Esteban Ballestar⁵, Nuria Barbarroja¹, Eduardo Collantes-Estévez² and Chary Lopez-Pedrera¹, ¹Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ³Hospital Universitario Reina Sofía, Córdoba, Spain, ⁴IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, ⁵Josep Carreras Institute (IJC), Badalona, Spain
Background/Purpose: 1. To develop integrated analyses of the genome-wide DNA methylation and gene expression profiles in monocytes from APS patients and assess their involvement in…
Abstract Number: 1634 • ACR Convergence 2020
Etiologies and Management of Hemophagocytic Lymphohistiocytosis: Is It Time for an Updated Protocol and Targeted Treatments?
Therese Posas-Mendoza¹, Cara McLeod¹, William Davis² and Robert Quinet², ¹Ochsner Medical Center, New Orleans, LA, ²Dept of Rheumatology, Ochsner Medical Center, New Orleans, LA
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease characterized by immune-overstimulation and a hyperinflammatory response resulting in cytokine storm and multi-organ failure.1 Secondary HLH…
Abstract Number: 2046 • ACR Convergence 2020
Alterations in Circulating CD4+ T Cell Phenotypes in CCP+ Early RA and CCP+ At-risk Individuals by Mass Cytometry
Ye Cao¹, Joshua Keegan², Alessandra Zaccardelli², Gregory Keras³, Jennifer Seifert⁴, Elizabeth Bemis⁵, Marie Feser⁶, M Kristen Demoruelle⁷, Kevin D. Deane⁸, Jill Norris⁵, Michael Brenner⁹, James Lederer¹⁰, V Michael Holers⁶, Jeffrey Sparks¹¹ and Deepak Rao², ¹Brigham and Women’s Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁴Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Littleton, CO, ⁵Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁶Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁷University of Colorado, Denver, CO, ⁸2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁰BWH Harvard Medical School, Boston, MA, ¹¹Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The cyclic citrullinated peptide (CCP) autoantibody is a highly specific and predictive marker for the clinical diagnosis of RA. Elevation in CCP titers can be…
Abstract Number: 0014 • ACR Convergence 2020
Does the Type of Rheumatic Disease or Biologic Treatment Increase the Risk of Developing Severe COVID-19?
Fernando López-Gutierrez¹, Antía García-Fernández¹, Jesús Loarce-Martos¹, Laura Calvo-Sanz¹, Ivan Del Bosque-Granero², Veronica Garcia², Boris Blanco-Cáceres¹, Cristina Pijoan-Moratalla¹, Lourdes Villalobos-Sánchez³, Javier Bachiller-Corral¹ and Mónica Vázquez¹, ¹Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ²Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ³Rheumatology, Hospital Universitario Ramón y Cajal, Madrid
Background/Purpose: Patients with inflammatory rheumatic diseases (IRD) have an increased risk for infection related to immunosuppression secondary to their disease, treatment and comorbidities. Nonetheless recent…
Abstract Number: 0300 • ACR Convergence 2020
Exposure to Topical Antimicrobials Reduces Inflammatory Gene Expression in Cutaneous Lupus Lesional Skin
Sirisha Sirobhushanam¹, Allison Billi², Alex Tsoi², Celine Berthier², Johann Gudjonsson³ and J. Michelle Kahlenberg⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan, Ann ArborUniversity of Michigan, ⁴Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Lupus lesional skin has elevated interferon expression, is highly colonized with Staphylococcus aureus (50%) and has no FDA-approved treatment options. S. aureus is known…
Abstract Number: 0559 • ACR Convergence 2020
Low Frequency of ANA/DFS70 Pattern Positive Result in a Large Cohort of Autoimmune/autoinflammatory Diseases Compared with First Degree Relatives and Healthy Controls Evaluated in a Single Hospital from Colombia
Consuelo Romero-Sanchez¹, Omar-Javier Calixto², Veronica Romero², Diana Rincon Riano³, Julio Amador², Luis Castro², Pedro Lopez-Mojica⁴, Daniela Marin², Diana Àcero⁵, Monica Acevedo⁵, Wilson Bautista-Molano⁶ and Juan Manuel Bello-Gualtero⁷, ¹Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada / Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada /Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, ²Hospital Militar Central, Universidad Militar Nueva Granada, Bogota, Colombia, ³Universidad Militar Nueva Granada, Bogota, Colombia, ⁴Hospital Militar Central, Universidad Militar Nueva Granada, BOGOTA, Distrito Capital de Bogota, Colombia, ⁵Hospital Militar Central, Bogota, Colombia, ⁶University Hospital Fundación Santa Fé de Bogotá and Universidad El Bosque, Bogotá, Colombia, ⁷Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada/ Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia
Background/Purpose: Autoimmune systemic rheumatic disease (SARD) diagnostic approach is complex and recently there are some diagnostic tools to rule-out autoimmune disease diagnoses. ANAS/DFS70 antibodies have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].